Periodic benefit-risk evaluation reports have substantial promise to guide patient care and should be made publicly available

Pharmacoepidemiology and Drug Safety

Volumn 26, Issue 5, 2017, Pages 597-599

  Fralick, Michael ^a,b   Kesselheim, Aaron S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RIVAROXABAN; WARFARIN;

CLINICAL EFFECTIVENESS; COHORT ANALYSIS; DRUG APPROVAL; DRUG INDUSTRY; ELECTRONIC HEALTH RECORD; EUROPEAN MEDICINES AGENCY; EVALUATION STUDY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PERSONNEL; HUMAN; INTERVENTION STUDY; NOTE; PATIENT CARE; PRIORITY JOURNAL; RARE DISEASE; ADVERSE DRUG REACTION; INTERPERSONAL COMMUNICATION; STANDARDS; UNITED STATES;

DISCLOSURE; DRUG APPROVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; PATIENT CARE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85013188102     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.4177     Document Type: Note

References (9)

1. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). Providing postmarketing periodic safety reports in the ICH E2C(R2) format (periodic benefit–risk evaluation report) guidance for industry, 2016.
2. European Medical Agency. Single, central platform now mandatory for all periodic safety update reports, 2016. http://esubmission.ema.europa.eu/psur/docs/psur_docs/News%20item%20-%20PSUR%20repository%20becomes%20mandatory.pdf [Accessed 12 Jan 2017].
3. European Medical Agency. Guideline on good pharmacovigilance practices (GVP) – module VII – periodic safety update report (Rev 1), 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/04/WC500142468.pdf [Accessed 14 Jan 2017].
4. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). E2C(R2) periodic benefit risk evaluation report (PBRER) guidance for industry, 2016. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm299513.pdf [Accessed 2 October 2016].
5. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. About ICH, 2016. http://www.ich.org/home.html. [Accessed 14 Jan 2017].
6. Kesselheim AS, Myers JA, Avorn J. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA 2011; 305(22): 2320–2326.
7. Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf 2010; 19(8): 858–868.
8. Lund JL, Richardson DB, Stürmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep 2015; 2(4): 221–228.
9. Rodriguez EM, Staffa JA, Graham DJ. The role of databases in drug postmarketing surveillance. Pharmacoepidemiol Drug Saf 2001; 10: 407–410.